Remedy Pharmaceuticals to Showcase Groundbreaking Phase 3 CHARM Study Data on CIRARA® at International Stroke Conference 2025
NEW YORK, Jan. 29, 2025 /PRNewswire/ -- Remedy Pharmaceuticals, the developer of CIRARA (intravenous glyburide) for the treatment of Large Hemispheric Infarction (LHI) today announced three speaker presentations of efficacy